

Datasheet: MCA797

BATCH NUMBER 169447

Description:	MOUSE ANTI HUMAN TGF BETA
Specificity:	TGF BETA
Other names:	TRANSFORMING GROWTH FACTOR BETA
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	TB21
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry (1)	▪			
Immunohistology - Frozen	▪			
Immunohistology - Paraffin (2)	▪			
ELISA	▪			
Immunoprecipitation			▪	
Western Blotting	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

(1) **Membrane permeabilization is required for this application. The use of Leucoperm (Product Code [BUF09](#)) is recommended for this purpose.**

(2) **Mouse anti Human TGF β antibody, clone TB21 has been used successfully on FFPE tissues without pretreatment e.g. ([Bob et al. 2011](#) and [Booth et al. 2002](#)). Others have used either [citrate pH6.0](#), [EDTA pH8.0](#) or [pepsin](#) mediated antigen retrieval.**

Target Species	Human
Species Cross Reactivity	Reacts with: Rat, Sheep, Mustelid, Mink, Rabbit, Mouse N.B. Antibody reactivity and working conditions may vary between species. Cross

reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.

Product Form	Purified IgG - liquid
---------------------	-----------------------

Preparation	Purified IgG prepared by affinity chromatography on Protein G from ascites
--------------------	--

Buffer Solution	Phosphate buffered saline
------------------------	---------------------------

Preservative Stabilisers	<0.1% Sodium Azide (NaN ₃)
---------------------------------	--

Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
---------------------------------------	-----------------------------

Immunogen	Human Transforming Growth Factor Beta 1 from platelets.
------------------	---

External Database Links	UniProt: P01137 Related reagents Entrez Gene: 7040 TGFB1 Related reagents
--------------------------------	--

Synonyms	TGFB
-----------------	------

RRID	AB_2201912
-------------	------------

Fusion Partners	Spleen cells from immunised Balb/c mice were fused with cells of the SP2/0-Ag 14 mouse myeloma cell line.
------------------------	---

Specificity	Mouse anti Human TGF beta antibody, clone TB21 recognizes both human platelet-derived and recombinant TGF-beta1 in enzyme-linked immunosorbent assay (ELISA). Mouse anti Human TGF beta antibody, clone TB21 demonstrates neutralising activity against TGF-beta1 in cell proliferation assays. Mouse anti Human TGF beta antibody, clone TB21 has been demonstrated to react with dimeric (~25 kDa) or monomeric (~12.5 kDa) molecules of natural TGF-beta1 under non-reducing and reducing conditions respectively.
--------------------	--

Flow Cytometry	Use 10ul of the suggested working dilution to label 1x10 ⁶ cells in 100ul
-----------------------	--

Histology Positive Control Tissue	Human Breast Carcinoma
--	------------------------

References	1. Nicotina, P.A. <i>et al.</i> (1997) Segmental up-regulation of transforming growth factor-beta in the pathogenesis of primary megarecter. An immunocytochemical study. Br J Urol. 80: 946-9. 2. Omer, F.M. and Riley, E.M. (1998) Transforming growth factor beta production is
-------------------	---

- inversely correlated with severity of murine malaria infection. [J Exp Med. 188: 39-48.](#)
3. Brown, H. *et al.* (1999) Cytokine expression in the brain in human cerebral malaria. [J Infect Dis. 180: 1742-6.](#)
 4. Lavaud, S. *et al.* (2001) Inflammation is probably not a prerequisite for renal interstitial fibrosis in normoglycemic obese rats. [Am J Physiol Renal Physiol. 280: F683-94.](#)
 5. Sheu, B.C. *et al.* (2001) Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. [J Immunol. 167: 2972-8.](#)
 6. Fernandez, T. *et al.* (2002) Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. [J Exp Med. 195: 1247-55.](#)
 7. Ueda, S. *et al.* (2003) Transforming growth factor-beta1 released from the spleen exerts a growth inhibitory effect on liver regeneration in rats. [Lab Invest. 83: 1595-603.](#)
 8. Kingston, P.A. *et al.* (2003) Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. [Circulation. 108: 2819-25.](#)
 9. Paalangara, R. *et al.* (2003) Intestinal exposure to a parasite antigen in utero depresses cellular and cytokine responses of the mucosal immune system. [Vet Immunol Immunopathol. 93: 91-105.](#)
 10. Hsiao, Y.W. *et al.* (2004) Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. [J Immunol. 172: 1508-14.](#)
 11. Moussay, E. *et al.* (2006) *Escherichia coli* Shiga toxin 1 enhances il-4 transcripts in bovine ileal intraepithelial lymphocytes. [Vet Immunol Immunopathol. 113: 367-82.](#)
 12. Helske, S. *et al.* (2006) Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. [Eur Heart J. 27: 1495-504.](#)
 13. Hopkinson, A. *et al.* (2006) Amniotic membrane for ocular surface reconstruction: donor variations and the effect of handling on TGF-beta content. [Invest Ophthalmol Vis Sci. 47: 4316-22.](#)
 14. Sumpster, T.L. *et al.* (2007) Regulation of the NFAT pathway discriminates CD4+CD25+ regulatory T cells from CD4+CD25- helper T cells. [J Leukoc Biol. 83: 708-17.](#)
 15. Buss, A. *et al.* (2008) TGF-beta1 and TGF-beta2 expression after traumatic human spinal cord injury. [Spinal Cord. 46: 364-71.](#)
 16. Lyras, D.N. *et al.* (2010) Temporal and spatial expression of TGF-beta1 in an Achilles tendon section model after application of platelet-rich plasma. [Foot Ankle Surg. 16: 137-41.](#)
 17. Lehr, E.J. *et al.* (2010) Decellularization reduces immunogenicity of sheep pulmonary artery vascular patches. [J Thorac Cardiovasc Surg. 141: 1056-62.](#)
 18. Calveley, V.L. *et al.* (2010) Genistein can mitigate the effect of radiation on rat lung tissue. [Radiat Res. 173: 602-11.](#)
 19. Mahmood, J. *et al.* (2011) Mitigation of lung injury after accidental exposure to radiation. [Radiat Res. 176: 770-80.](#)
 20. Bob, F.R. *et al.* (2011) Histological changes and immunohistochemical markers in the assessment of glomerulosclerosis in patients with glomerulonephritis. [Rom J Morphol Embryol. 52: 1027-32.](#)
 21. Braun, N. *et al.* (2011) Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum--implications for therapeutic targets to prevent encapsulating peritoneal sclerosis. [Perit Dial Int. 31: 291-300.](#)
 22. Westermann, D. *et al.* (2011) Cardiac inflammation contributes to changes in the

extracellular matrix in patients with heart failure and normal ejection fraction. [Circ Heart Fail. 4: 44-52.](#)

23. Kim, M. *et al.* (2013) Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. [PLoS One. 8 \(1\): e53630.](#)

24. Bob, F. *et al.* (2014) Immunohistochemical study of tubular epithelial cells and vascular endothelial cells in glomerulonephritis. [Ren Fail. 36: 1208-14.](#)

25. Gomaa, W.M. *et al.* (2014) Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients. [Saudi J Gastroenterol. 20 \(1\): 59-65.](#)

26. Yusup, A. *et al.* (2015) Bone marrow lesions, subchondral bone cysts and subchondral bone attrition are associated with histological synovitis in patients with end-stage knee osteoarthritis: a cross-sectional study. [Osteoarthritis Cartilage. 23 \(11\): 1858-64.](#)

27. Hu, H-Y. *et al.* (2016) ATRA alleviated endometrial fibrosis in a rabbit intrauterine adhesions model through downregulation of the TGF- β 1/smad4 signaling pathway. [Int J Clin Exp Pathol 9\(6\): 6171-8.](#)

28. Elkabir, M.A. *et al.* (2016) Efficacy of azithromycin and metronidazole combined therapy on rats' gingival overgrowth induced by cyclosporine-A: An experimental animal study. [J Oral Biol Craniofac Res. 6 \(3\): 219-226.](#)

29. Attia, G.M. *et al.* (2017) Autologous platelet rich plasma enhances satellite cells expression of MyoD and exerts angiogenic and antifibrotic effects in experimental rat model of traumatic skeletal muscle injury [Egypt J Histol 40 \(4\): 443-58.](#)

30. Dagnelie, M.A. *et al.* (2019) *Cutibacterium acnes* phylotypes diversity loss: a trigger for skin inflammatory process. [J Eur Acad Dermatol Venereol. 33 \(12\): 2340-2348.](#)

31. Abd-Elhafez, A. *et al.* (2021) The possible curative role of bone marrow-derived mesenchymal stem cells in bleomycin-induced skin changes in adult male albino rats [Egyptian Journal of Histology. 45 \(4\): 1125-45.](#)

32. Attia, S.H. *et al.* (2024) Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGF β /SMAD pathway. [Naunyn Schmiedebergs Arch Pharmacol. Feb 20 \[Epub ahead of print\].](#)

33. Galil T.I.A. *et al.* (2023) Improvement of kidney injury molecule-1 (KIM-1) and N-acetylglucosaminidase (NAG) in the kidney following platelet rich plasma (PRP) administration in the treatment of cyclosporine A-induced nephrotoxicity in adult male albino rats [Egyptian Journal of Histology. 47 \(1\): 268-83.](#)

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee

12 months from date of despatch

Health And Safety Information

Material Safety Datasheet documentation #10040 available at: <https://www.bio-rad-antibodies.com/SDS/MCA797>
10040

Related Products

Recommended Secondary Antibodies

Rabbit Anti Mouse IgG (STAR12...)	RPE
Goat Anti Mouse IgG IgA IgM (STAR87...)	HRP
Goat Anti Mouse IgG (STAR76...)	RPE
Goat Anti Mouse IgG (STAR70...)	FITC
Goat Anti Mouse IgG (H/L) (STAR117...)	Alk. Phos. , DyLight®488 , DyLight®550 , DyLight®650 , DyLight®680 , DyLight®800 , FITC , HRP
Rabbit Anti Mouse IgG (STAR13...)	HRP
Goat Anti Mouse IgG (Fc) (STAR120...)	FITC , HRP
Rabbit Anti Mouse IgG (STAR9...)	FITC
Goat Anti Mouse IgG (STAR77...)	HRP

Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL \(MCA928\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M433344:241008'

Printed on 08 Oct 2024